Japanese researchers found that lecanemab, an amyloid-clearing drug for Alzheimer’s, does not improve the brain’s waste clearance system in the short term. This implies that nerve damage and impaired clearance occur early and are difficult to reverse. Their findings underscore that tackling amyloid alone may not be enough to restore brain function, urging a broader approach to treatment.
could be, but this is hard to prove. And then we have ask what about people who wouldn’t get Alzheimer’s, is there harm from giving them to them? Lots of other questions come up when treating normal people that we can ignore for those who need help. (if this revered Alzheimers but caused death by Cancer in 5 years it is still worth it for those with Alzheimers)